Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 5/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL621014 | 0.87 | TAS1R3 (0.38) | TAS1R3TAS1R1ATMEPHX1CHRNB4 | |
| SCHEMBL18347952 | 0.87 | TAS1R3 (0.38) | TAS1R3TAS1R1ATMEPHX1CHRNB4 | |
| SCHEMBL24778822 | 0.86 | MMP2 (0.53) | TAS1R3TAS1R1ATMEPHX1 | |
| SCHEMBL16123028 | 0.85 | TAS1R3 (0.44) | TAS1R3TAS1R1ATMTSHRALDH1A1 | |
| SCHEMBL23479840 | 0.83 | TAS1R3 (0.53) | TAS1R3TAS1R1EPHX1SMN1; SMN2 | |
| SCHEMBL21100961 | 0.83 | PTGS1 (0.38) | TAS1R3TAS1R1ATMCHRNB4CHRNA3 | |
| SCHEMBL23479839 | 0.83 | TAS1R3 (0.53) | TAS1R3TAS1R1EPHX1SMN1; SMN2 | |
| SCHEMBL16373137 | 0.83 | PTGS1 (0.38) | TAS1R3TAS1R1ATMCHRNB4CHRNA3 | |
| SCHEMBL19755664 | 0.83 | PTGS1 (0.38) | TAS1R3TAS1R1ATMCHRNB4CHRNA3 | |
| SCHEMBL13380101 | 0.83 | PTGS1 (0.38) | TAS1R3TAS1R1ATMCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791092-B2 | Molecular tweezers for the treatment of amyloid-related diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-07-29 | — | — | US | disclosed |
| US-20120108548-A1 | MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108548-A1 | MOLECULAR TWEEZERS FOR THE TREATMENT OF AMYLOID-RELATED DISEASES | APP, PSEN1, PSEN2 | TAS1R3 3383/4885TAS1R1 3785/4885ATM 2075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.